BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 28258343)

  • 1. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
    Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
    J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
    Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
    Döring M; Müller C; Johann PD; Erbacher A; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Oct; 12():263. PubMed ID: 23082876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.
    Tragiannidis A; Herbrüggen H; Ahlmann M; Vasileiou E; Gastine S; Thorer H; Fröhlich B; Müller C; Groll AH
    J Antimicrob Chemother; 2019 Dec; 74(12):3573-3578. PubMed ID: 31504563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Heinz WJ; Cabanillas Stanchi KM; Klinker H; Blume O; Feucht J; Hartmann U; Feuchtinger T; Lang P; Handgretinger R; Döring M
    Med Mycol; 2016 Feb; 54(2):128-37. PubMed ID: 26483433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
    Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
    Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
    J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
    Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
    Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I
    Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole delayed-release tablets in paediatric haematology-oncology patients.
    Mauro M; Colombini A; Perruccio K; Zama D; D'Amico MR; Calore E; Carraro F; Muggeo P; Tridello G; Baretta V; Cesaro S
    Mycoses; 2020 Jun; 63(6):604-609. PubMed ID: 32246512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
    Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
    Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
    Döring M; Cabanillas Stanchi KM; Klinker H; Eikemeier M; Feucht J; Blaeschke F; Schwarze CP; Ebinger M; Feuchtinger T; Handgretinger R; Heinz WJ
    Med Mycol; 2017 Jun; 55(4):375-384. PubMed ID: 27703016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.